US supreme court ends Sandoz–Amgen biosimilar dispute
By 
Rebecca Trager2021-05-25T13:00:00
Sandoz’s copy of arthritis drug Enbrel won’t be available in the US until 2029, 30 years after it was first marketed
The US supreme court has rejected a high-profile bid by Novartis’ generics arm Sandoz to challenge two of Amgen’s key patents for its blockbuster arthritis treatment Enbrel (etanercept). The decision means that Sandoz cannot launch its generic etanercept biosimilar in the US until 2029. In Europe, Sandoz has had its product, Erelzi, on the market since 2017.